Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Desloratadine
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
{{Short description|Allergy medication}} {{Use dmy dates|date=May 2024}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Infobox drug | verifiedrevid = 460777963 | image = Desloratadine.svg | image_class = skin-invert-image | width = 222 | alt = | image2 = Desloratadine 3D ball-and-stick.png | alt2 = <!-- Clinical data --> | pronounce = | tradename = Aerius, others<ref name="murdoch">{{cite journal | vauthors = Murdoch D, Goa KL, Keam SJ | title = Desloratadine: an update of its efficacy in the management of allergic disorders | journal = Drugs | volume = 63 | issue = 19 | pages = 2051β2077 | date = 7 April 2003 | pmid = 12962522 | doi = 10.2165/00003495-200363190-00010 | s2cid = 195689362 }}</ref> | Drugs.com = {{drugs.com|monograph|desloratadine}} | MedlinePlus = a602002 | DailyMedID = Desloratadine | pregnancy_AU = B1 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = [[Oral administration|By mouth]] | class = [[Anti-allergic agent]] | ATC_prefix = R06 | ATC_suffix = AX27 | ATC_supplemental = <!-- Legal status --> | legal_AU = S2 | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> | legal_BR_comment = | legal_CA = OTC | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = <ref name="Clarinex FDA label">{{cite web | title=Clarinex- desloratadine tablet, film coated | website=DailyMed | date=14 November 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c671342e-69a2-4ca5-abc2-8166ed4240d4 | access-date=18 May 2024}}</ref><ref>{{cite web | title=Clarinex-D 12 HOUR- desloratadine and pseudoephedrine sulfate tablet, extended release | website=DailyMed | date=14 November 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af66b7a-4ab8-40d8-abdd-22d3310228a8 | access-date=18 May 2024}}</ref> | legal_EU = Rx-only | legal_EU_comment = /{{nbsp}}OTC<ref name="Desloratadine ratiopharm EPAR">{{Cite web|url=https://www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-ratiopharm|title=Desloratadine ratiopharm EPAR |website=[[European Medicines Agency]] (EMA) | date=13 January 2012 | access-date=23 March 2025 }}</ref><ref name="Neoclarityn EPAR">{{Cite web|url=https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn|title=Neoclarityn EPAR |website=[[European Medicines Agency]] (EMA) | date=15 January 2001 | access-date=23 March 2025 }}</ref><ref>{{cite web | title=Aerius EPAR | website=[[European Medicines Agency]] (EMA) | date=15 January 2001 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/aerius | access-date=24 March 2025}}</ref> | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = <!-- For countries not listed above --> <!-- Pharmacokinetic data --> | bioavailability = Rapidly absorbed | protein_bound = 83 to 87% | metabolism = [[UGT2B10]], [[CYP2C8]] | metabolites = 3-Hydroxydesloratadine | onset = within 1 hour | elimination_half-life = 27 hours, 33.7 hours in elderly patients<ref name="Clarinex FDA label" /> | duration_of_action = up to 24 hours | excretion = 40% as conjugated metabolites into urine<br />Similar amount into the feces <!-- Identifiers --> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 100643-71-8 | CAS_supplemental = | PubChem = 124087 | IUPHAR_ligand = 7157 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00967 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 110575 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = FVF865388R | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D03693 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 291342 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1172 | NIAID_ChemDB = | PDB_ligand = | synonyms = descarboethoxyloratadine<ref name="loratadine-fda-2000">{{cite web |author1=Schering Corporation |title=CLARITIN brand of Loratadine - Full Prescribing Information (US FDA) |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf |website=US FDA |access-date=17 May 2024 |date=2000 |quote="loratadine is metabolized to descarboethoxyloratadine predominantly by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, by cytochrome P450 2D6 (CYP2D6)."}}</ref> <!-- Chemical and physical data --> | IUPAC_name = 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5''H''-benzo[5,6]cyclohepta[1,2-b]pyridine | C=19 | H=19 | Cl=1 | N=2 | smiles = Clc4cc2c(C(/c1ncccc1CC2)=C3/CCNCC3)cc4 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2 | StdInChI_comment = | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = JAUOIFJMECXRGI-UHFFFAOYSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} <!-- Definition and medical uses --> '''Desloratadine''' sold under the brand name '''Aerius''' among others, is a [[tricyclic]] [[H1 antagonist|H<sub>1</sub> inverse agonist]] that is used to treat [[allergy|allergies]]. It is an [[active metabolite]] of [[loratadine]]. <!-- Society and culture --> It was patented in 1984 and came into medical use in 2001.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=549 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA549 }}</ref> It was brought to the market in the US by Schering Corporation, later named [[Schering-Plough]].<ref name="Clarinex FDA label" />
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)